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We thank Roozenbeek and colleagues for their interest in our recent work.1 The clinical 
significance of the ischemic penumbra in patients treated with intravenous thrombolysis is 
well established.2 The term mismatch has become colloquially used to describe the situation 
where the relative volume of a patient’s infarct core is less than the total perfusion lesion, 
thus representing the penumbra. Target mismatch is simply a way of defining a group of 
patients with a relatively large penumbra that is salvageable from infarction with effective 
reperfusion. In patients without such a target mismatch, there is limited brain tissue to 
salvage, and this translates clinically into less benefit from reperfusion.3 Therefore, we 
believe that clear biological plausibility exists for treating patients with target mismatch, and 
we explored this hypothesis in our analysis. We agree that secondary analyses of pooled data 
must be regarded with caution and that 1 appropriate statistical approach is to seek evidence 
of a perfusion profile-treatment group interaction. In this exploratory secondary analysis, one 
would not expect to find robust evidence of such an interaction. This outcome could only be 
derived from an appropriately designed clinical trial of sufficient sample size, which is not 
currently available from either the intravenous or endovascular trials. We believe, however, 
that the findings of our pooled analysis support the possibility that improved reperfusion seen 
with tenecteplase translated into better clinical outcomes in patients with more tissue to 
salvage (ie, target mismatch patients). Our findings offer support to the possibility that 
tenecteplase might have advantages over existing thrombolytic therapy with alteplase and 
yield some preliminary estimates of treatment effect sizes in patients selected by target 
mismatch profile compared with unselected cases or those without target mismatch, which is 
of benefit in the design of future clinical trials. We certainly agree that our analysis was 
underpowered to detect a weaker treatment effect. 
Finally, we must thank Roozenbeek and colleagues for their mention of the need for phase III 
trials.1 Debates will always take place about trial design in stroke and whether to include all 
patients (lumping) or select those most likely to benefit from the intervention (splitting).4 For 
the selection of patients for thrombectomy, for example, the lumping approach taken in MR 
CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute 
Ischemic Stroke in the Netherlands) may lead to futile treatment with health economic 
impacts that even the wealthiest economies could not absorb. The splitting approach to 
patient selection used in EXTEND IA (Extending the Time for Thrombolysis in Emergency 
Neurological Deficits–Intra-arterial) or SWIFT-PRIME (Solitaire With the Intention For 
Thrombectomy as PRIMary Endovascular Treatment ) may be a more cost-effective 
approach.5 Time will tell. Because we are all for freedom of choice, our teams based in 
Australia and Scotland are currently undertaking the TASTE trial (Tenecteplase versus 
Alteplase for Stroke Thrombolysis Evaluation) and the ATTEST 2 trial (Alteplase-
Tenecteplase Trial Evaluation for Stroke Thrombolysis 2), respectively. TASTE uses target 
mismatch selection criteria, whereas ATTEST 2 has broader inclusion criteria. Both will 
examine the question of whether intravenous tenecteplase leads to superior outcomes 
compared with intravenous alteplase in acute ischemic stroke. We would like to extend a 
warm invitation to our colleagues to participate in either (or both) trials. 
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